Nonhematopoietic Variants of Erythropoietin in Ischemic Stroke: Need for Step-Wise Proof-of-Concept Studies
Neuroprotective, but not hematopoietic, variants of erythropoietin (EPO), such as Neuro-EPO, are promising candidates for treatment in the acute and subacute stroke phase. Characterized by its low sialic acid content and therefore exhibiting a very short plasma half-life, Neuro-EPO can probably not...
Saved in:
Main Author: | Dirk M. Hermann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2010.226 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Targets of Neuroprotection in Ischemic Stroke
by: Marco Bacigaluppi, et al.
Published: (2008-01-01) -
The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
by: Julio Cesar García-Rodríguez, et al.
Published: (2009-01-01) -
Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
by: Umberto Vespasiani-Gentilucci, et al.
Published: (2018-01-01) -
Conception of understanding in mathematical proof
by: V. V. Tselishchev, et al.
Published: (2021-12-01) -
Erythrocytes and Erythropoietin
by: Michael Föller, et al.
Published: (2011-01-01)